The West Nile virus (WNV) NS5 protein contains a methyltransferase (MTase) domain involved in RNA capping and an RNA-dependent RNA polymerase (RdRp) domain essential for virus replication. Crystal structures of individual WNV MTase and RdRp domains have been solved; however, the structure of full-length NS5 has not been determined. To gain more insight into the structure of NS5 and interactions between the MTase and RdRp domains, we generated a panel of seven monoclonal antibodies (mAbs) to the NS5 protein of WNV (Kunjin strain) and mapped their binding sites using a series of truncated NS5 proteins and synthetic peptides. Binding sites of four mAbs (5D4, 4B6, 5C11 and 6A10) were mapped to residues 354-389 in the fingers subdomain of the RdRp. This is consistent with the ability of these mAbs to inhibit RdRp activity in vitro and suggests that this region represents a potential target for RdRp inhibitors. Using a series of synthetic peptides, we also identified a linear epitope (bound by mAb 5H1) that mapped to a 13 aa stretch surrounding residues 47 and 49 in the MTase domain, a region predicted to interact with the palm subdomain of the RdRp. The failure of one mAb (7G6) to bind both N-and Cterminally truncated NS5 recombinants indicates that the antibody recognizes a conformational epitope that requires the presence of residues in both the MTase and RdRp domains. These data support a structural model of the full-length NS5 molecule that predicts a physical interaction between the MTase and the RdRp domains.
INTRODUCTION
Flaviviruses include a number of arthropod-borne viruses responsible for several globally significant diseases such as dengue, Japanese encephalitis and West Nile fever. West Nile virus (WNV) is a mosquito-transmitted virus found in parts of Africa, Asia, Europe and the Americas that is responsible for outbreaks of fever and fatal encephalitis in humans, horses and birds. Like all flaviviruses, WNV has a single-stranded positive-sense RNA genome with a 59 type I cap structure (m 7 GpppAmG) (Westaway et al., 2002) . The genome encodes 10 proteins (three structural and seven nonstructural) in a single open reading frame flanked by 59-and 39-non-coding regions that contain conserved secondary structures important for genome replication (Westaway et al., 2002) .
The flavivirus NS5 protein is a large (100 kDa), highly conserved, multifunctional molecule involved in viral RNA replication. NS5 comprises an N-terminal methyltransferase (MTase) domain that catalyses both guanine N-7 and ribose 29-O methylations during viral RNA cap formation (Zhou et al., 2007) and a C-terminal domain that harbours the RNA-dependent RNA polymerase (RdRp) (Tan et al., 1996; Guyatt et al., 2001; Nomaguchi et al., 2004; Selisko et al., 2006) . The crystal structure of the WNV RdRp revealed classic RdRp structure bearing palm, thumb and finger subdomains (Malet et al., 2007) .
The essential role of NS5 in flavivirus replication makes it an attractive antiviral target (Malet et al., 2008) . Thus, the structure of the full-length molecule is required to provide a more accurate model for functional analysis and drug design. While recent studies have elucidated separate crystal structures for the MTase and RdRp domains of WNV NS5 (Malet et al., 2007; Zhou et al., 2007) , apparent instability of the full-length recombinant protein during purification precluded crystallization of the entire molecule. A possible solution to this dilemma is co-purification and co-crystallization of NS5 in the presence of a monoclonal antibody (mAb) that binds to both MTase and RdRp domains and stabilizes the full-length protein.
Here, we report the generation of a panel of mAbs to the WNV NS5 protein and the use of truncated recombinant NS5 proteins and synthetic peptides to map their binding sites on the protein. These antibodies were also assessed for their ability to inhibit RdRp activity in vitro, as a means to define potential targets for antiviral drugs.
METHODS
Virus and cell culture. C6/36 (mosquito salivary gland) cells were cultured in RPMI (Gibco) supplemented with 2 % fetal bovine serum (Gibco), 50 U penicillin ml 21 , 50 mg streptomycin ml 21 and 50 ml Glutamax ml 21 (Gibco). All cells were passaged by dissociating the cell monolayer from the flask with trypsin/PBS and were cultured at 28 uC. Viruses used to infect C6/36 cells for fixed-cell ELISA (Clark et al., 2007) were WNV MRM61C Kunjin strain (WNV KUN ) (GenBank accession no. D00246); WNV NY99-43216 strain (WNV NY99 ) (AF196835); WNV Sarafend strain (WNV Sarafend ) (AY688948); WNV prototype strain B956 (WNV B956 ) (M12294); Koutango virus (KOUV); Murray Valley encephalitis virus 1/51 strain (MVEV); Japanese encephalitis virus Nakayama strain (JEV); dengue virus type 2 New Guinea strain (DENV2); yellow fever virus 17-D strain (YFV); and Kokobera virus strain MRM32 (KOKV). Cells in 96-well plates were infected at an m.o.i. of 0.1 and incubated for 5 days before removing the culture supernatant and fixing cells in 20 % acetone for 2 h at 4 uC. Plates were then air-dried and stored at 220 uC until use. Cultures for cell lysate preparation were infected and incubated in a similar manner before cells were rinsed in PBS and disrupted by sonication in the presence of lysis buffer (PBS containing 1 % Triton X-100 and 0.1 % SDS). The lysate was clarified by centrifugation at 12 000 g for 10 min at 4 uC and stored at 270 uC.
Mouse immunization for hybridoma production. Adult female BALB/c mice were immunized subcutaneously (s.c.) at four sites on the abdomen with 2.5 mg purified, recombinant WNV KUN NS5 protein (rNS5) mixed with an equal volume of adjuvant (MPL+TDM+CWS; Sigma no. M-6661) in a total volume of 50 ml per injection site. A second identical immunization was performed 3 weeks later. A final boost (5 mg rNS5 by both intraperitoneal and s.c. injection) using the same antigen : adjuvant ratio was given 7 weeks after the initial injection. Four days after the final boost, mouse spleens were removed for hybridoma production by fusion of spleen B cells with myeloma cells as previously described (Clark et al., 2007) .
Plasmids. All WNV KUN -coding sequences for RdRp domains and the full-length NS5 protein were cloned into the vector pDEST14 using the Gateway system (Life Technologies) with an N-terminal 6His tag. The N-terminally truncated recombinant plasmids used in this study have been described previously (Malet et al., 2007) . C-terminal deletion constructs (Fig. 2a) were generated by PCR to delete Cterminal NS5 sequences from the full-length protein in pDEST14 NHis NS5. PCR products were then digested with EcoRI and selfligated.
rNS5 expression. Protein expression was performed as described previously (Malet et al., 2007) . pDEST14 constructs were expressed in Rosetta 2 (DE3) [pLysS] competent cells (Novagen). Briefly, after heat-shock transformation, protein expression was induced with 50 mM IPTG and a cold shock (30 min at 4 uC) followed by incubation at 30 uC overnight. Sonication was performed in sonication buffer (50 mM Na 2 PO 4 , 300 mM NaCl, 10 % glycerol, 5 mM MgCl 2 , pH 7.6) in the presence of protease inhibitor cocktail (Sigma) and 1 mg ml 21 chicken egg white lysozyme (Sigma) after 30 min incubation at 4 uC. Cell lysates were stored at 220 uC until further use.
Radio-immune precipitation (RIP) and Western blot. RIP assays were performed essentially as described previously (Roosendaal et al., 2006) . BHK cell monolayers (70-80 % confluent) in 60 mm diameter culture wells were infected with WNV KUN (m.o.i.55) ; at 28 h postinfection, the cells were starved in methionine-cysteine-deficient medium for 60 min and subsequently radiolabelled with 50 mCi ml
21
[ 35 S]methionine-cysteine (Trans-label; ICN) for a further 4 h. The radiolabelled cells were incubated on ice with reporter lysis buffer (Promega) for 10 min and harvested by scraping into microcentrifuge tubes. These were kept on ice for an additional 10 min. The lysate was clarified by centrifugation for 10 min at 12 000 g at 4 uC, and 150 ml of the resulting supernatant was immunoprecipitated with 6 ml neat hybridoma supernatant containing each anti-NS5 mAb as described previously (Westaway et al., 1997) . For Western blot, proteins were resolved on 4-12 % precast SDS-PAGE gels (Invitrogen), transferred to Hybond C nitrocellulose membranes (Amersham) and immunostained as described previously (Clark et al., 2007) . Dot-blot. A dot-blot was performed using a vacuum manifold dotblot apparatus (Bio-Rad) according to the manufacturer's instructions. Briefly, recombinant protein samples were diluted in PBS in 96-well flat bottomed plates then transferred to the dot-blot apparatus. Samples were then loaded onto the nitrocellulose membranes (Amersham) under vacuum. Membranes were stained following the Western blot protocol as described by Clark et al. (2007) .
RdRp inhibition assay. RdRp activity of WNV KUN NS5 was monitored by a test using a homopolymeric template poly(rC) and tritium-labelled GTP followed by filter-binding and liquid scintillation counting. Reactions were set up by preparing premixes which contained RdRp buffer and recombinant WNV KUN NS5 RdRp domain as described by Selisko et al. (2006) . For inhibition assays, supernatants of mAb hybridoma cultures (serum-free medium, Gibco; stabilized with 0.02 % azide) or dilutions thereof (1 : 5, 1 : 10 or 1 : 25) were added to the premixes. After pre-incubation for 10 min at 4 uC, reactions were started by adding GTP (100 mM) containing 0.01 mCi [
3 H]-GTP (GE Healthcare) per ml of reaction mixture. Reactions were incubated at 30 uC. After 5, 10 and 30 min, 10 ml samples were taken and the reaction was stopped by spotting them into 30 ml 50 mM EDTA in 96-well plates. Samples were then transferred to glass fibre filtermats with DEAE active groups (DEAE filtermat, Wallac) using a Filtermat Harvester (Packard Instruments). Filtermats were washed three times with 0.3 M ammonium formate, pH 8.0, and twice with water, once with ethanol; filtermats were dried and the filter was transferred into sample bags. Liquid scintillation fluid was added and incorporation was measured in counts per minute (c.p.m.) using a Wallac MicroBeta TriLux Liquid Scintillation Counter. Initial velocities were determined in the absence (100 % activity) and presence of mAbs.
Immunofluorescent antibody assay (IFA). Vero cells were grown on glass coverslips and infected with WNV KUN at an m.o.i. of 1 for 24 h, fixed in acetone then incubated with selected mAbs in hybridoma culture fluid (diluted 1 in 4 in PBS/1 % BSA) for 1 h at 37 uC, then washed and stained with goat anti-mouse Texas red conjugate (Sigma; 1 in 500 in PBS/1 % BSA) for 1 h at 37 uC. Coverslips were mounted with ProLong Anti-Fade (Invitrogen) and viewed under a confocal UV microscope (Zeiss), using the LSM Image software at a magnification of 406.
Peptide-antibody binding analysis. Synthetic peptides (Peptide 2.0) were designed from the NS5 protein based on the published sequence of WNV KUN (Coia et al., 1988) . A control peptide [comprising residues 579-613 of gp41 of human immunodeficiency virus type 1; Wilson et al., 1991] was a gift from Agen Biomedical. Peptides were solubilized in water, except for the control peptide which was solubilized in acetic acid, and peptide NS5-25I-19, which was solubilized in dimethylformamide. Following solubilization, peptides were tested by ELISA and microsphere immunoassay (Luminex) as described previously (Hobson-Peters et al., 2008) .
Competitive binding assays. Competitive binding between mAbs was assessed following the method of Hall et al. (1990) . Briefly, mAbs were purified using HiTrap Protein G columns (GE Healthcare) and biotinylated using the BiotinTag kit (Sigma) as per the manufacturer's instructions. Saturating dilutions of each unlabelled mAb were allowed to react with purified recombinant RdRp or full-length NS5 protein coated to ELISA plates for 1 h at 28 uC. Without washing, a non-saturating dilution of labelled 'competitor' mAb was added for 1 h at 28 uC. Following washing, horseradish peroxidase (HRP)-conjugated streptavidin (Invitrogen) was added and incubated for 30 min. The wells were washed prior to incubation with ABTS substrate (Clark et al., 2007) .
RESULTS

Specificity of mAbs for WNV strains
Seven hybridomas reactive to WNV KUN NS5 were isolated and mAbs were produced from each clone as clarified culture supernatant. Their reactivity to NS5 from different WNV strains and related flaviviruses was determined by fixed-cell ELISA (Table 1 ). All mAbs recognized the WNV KUN strain in ELISA; however, mAb 5H1 gave only weak reactions to other WNV strains (including KOUV) and failed to react with cells infected with other flaviviruses. mAbs 6A10, 3H6 and 5D4 also recognized the WNV NY99 strain, but failed to bind to fixed cells infected with other WNV strains or other flaviviruses. mAbs 5C11 and 7G6 recognized all WNV strains, while the latter also reacted with JEV and MVEV. mAb 4B6 showed an unusual binding pattern, with moderate reaction affinity to WNV KUN and WNV NY99 and strong binding to MVEV.
NS5 mAbs recognize conformational and linear epitopes in Western blot, RIP and IFA
Analysis of mAbs by Western blot revealed that only 5H1 recognized a 90-100 kDa protein corresponding to NS5 after resolution on SDS-PAGE (Fig. 1a) . When viral antigen was reduced and carboxymethylated prior to PAGE to ensure that no reformation of disulphide bridges could occur after the protein had been transferred to the membrane, 5H1 still bound to the NS5 protein, suggesting that it recognized a linear or continuous amino sequence in the protein (Fig. 1a, lane 4) . The remaining antibodies appeared to recognize conformational epitopes that were sensitive to SDS denaturation. However, mAbs 5D4, 6A10, 4B6 and 3H6 (weakly) were shown to immunoprecipitate NS5 extracted from infected cells lysed in the presence of non-ionic detergents (Fig. 1b) .
Analysis of acetone-fixed, WNV KUN -infected Vero cells by IFA using anti-NS5 mAbs 5H1, 4B6 and 3H6 revealed Table 1 . Reaction of anti-NS5 mAbs to a panel of WNV strains and related flaviviruses in fixed-cell ELISA ELISA was performed as described by Clark et al. (2007) . mAbs in hybridoma culture supernatant were titrated from 1/2 to 1/16. The mean OD 405 was measured in an automated plate reader and the dilution producing the maximum mean OD was scored as: ++, OD .1.0; +, OD .0.5 to 1.0; +/2, OD .0.25 to 0.5. The reaction was only scored as positive if the OD was .0.25 and at least twice the mean OD of the corresponding dilution of mAb on uninfected cells. 2  2  2  2  2  2  2  DENV2  2  2  2  2  2  2  2  YFV  2  2  2  2  2  2  2  Uninfected  2  2  2  2  2  2  2 staining throughout the cytoplasm with negligible nuclear localization of NS5 (Fig. 1c) , consistent with previous observations using polyclonal rabbit antiserum to WNV KUN NS5 (Malet et al., 2007; Mackenzie et al., 2007) . Other mAbs in the panel showed similar staining patterns (results not shown).
Viral antigen mAb
5H1 (IgG1/k) 7G6 (IgG1/k) 6A10 (IgG1/k) 3H6 (IgG1/k) 5D4 (IgG2a/k) 5C11 (IgG1/k) 4B6 (IgG1/k) WNV KUN ++ + + ++ ++ + + WNV NY99 +/2 + + ++ ++ + + WNV B956 +/2 + 2 2 2 + 2 WNV Sarafend +/2 + 2 2 2 + 2 KOUV +/2 + 2 2 2 + 2 MVEV 2 + 2 2 2 2 ++ JEV 2 + 2 2 2 2 2 KOKV
Expression of full-length and N-terminally truncated NS5
Recombinant full-length or truncated NS5 sequences were expressed in bacterial cells and extracted with minimal denaturation using sonication. Coomassie staining and Western blot analysis with an anti-6His antibody revealed that these fusion proteins were abundantly expressed in Escherichia coli and were of the predicted molecular masses ( Supplementary Fig. S1 , available in JGV Online).
Binding patterns of mAbs to N-terminally truncated WNV NS5 proteins
Lysates containing N-terminally truncated recombinant NS5 proteins were titrated by dot-blot and end points were determined by reaction with anti-6His antibody. Based on these results, the concentrations of each recombinant protein were equilibrated for testing the reaction of each mAb. Binding studies using dot-blot analysis showed that all mAbs recognized the full-length recombinant NS5 protein (Fig. 2b) . mAb 3H6 also bound each of the Nterminally truncated proteins, while mAbs 6A10, 4B6 and 5D4 failed to recognize recombinants lacking the first 389 residues. mAb 5C11 recognized rNS5 265-831, rNS5 289-859, rNS5 354-831 and rNS5 354-882, but failed to recognize recombinant NS5 with larger N-terminal truncations. These results indicate that mAb 3H6 recognizes amino acids in the region 390-831 of NS5, 5C11 requires NS5 residues 354-369 for binding and mAbs 6A10, 4B6 and 5D4 recognize amino acids between positions 370 and 389.
In contrast, mAbs 5H1 and 7G6 did not bind to any of the N-terminally truncated proteins tested, including an additional construct (rNS5 390-905) that contained the C-terminal residues of KUNV NS5 (results not shown). mAb 5H1 also failed to recognize the truncated NS5 proteins in a Western blot, although the full-length recombinant protein was clearly detected (data not shown). Together, the lack of binding by 5H1 to Nterminally truncated recombinants, and its recognition of linearized full-length protein in Western blot indicate that this antibody recognizes a linear or continuous epitope located in the first 264 residues of KUNV NS5. The requirement of the N-terminal 264 residues for binding of 7G6 was also apparent, although the conformational nature of the binding site (7G6 failed to recognize NS5 that had been exposed to SDS) suggests it may also involve other regions of the protein. The binding profiles of each mAb are summarized in Table 2 .
Generation of C-terminally truncated deletion constructs
To confirm the locality of the 5H1 epitope and further define the binding site of mAb 7G6 in the N-terminal region of NS5, additional C-terminally deleted constructs were generated to express residues 1-270, 1-370, 1-400 or 1-600 of WNV KUN NS5 (see Fig. 2a ). These recombinant antigens were titrated and concentrations equilibrated as above for analysis of mAb binding profiles in dot-blot.
mAb 5H1 bound strongly to all C-terminally truncated constructs, confirming the recognition of its epitope within the first 270 aa of WNV KUN NS5 (Fig. 2c, Table 2 ). However, mAb 7G6 failed to bind to any of these recombinant proteins, suggesting that it requires additional residues outside the first 600 aa to form its binding site. Further analysis of 7G6 binding to purified recombinant versions of the complete RdRp domain [residues 273-905; described as pol2 by Malet et al. (2007) ] and the full-length NS5 in ELISA, revealed negligible binding to the RdRp compared with a strong reaction with full-length recombinant NS5 ( Supplementary Fig. S2 , available in JGV Online). This is consistent with a conformational epitope, comprising multiple protein folds from both the RdRp and MTase domains of the protein. mAbs 4B6, 5C11, 5D4 and 3H6 only bound rNS5 1-600, suggesting that these mAbs also require residues between positions 400 and 600 for binding. The lack of binding to all C-terminally truncated NS5 constructs by mAb 6A10 indicates that residues 600-831 are also required in addition to 370-389. Together with the binding profiles generated from N-terminally truncated proteins, these data allow more accurate mapping of the regions in NS5 required for mAb binding (see Table 2 ).
Modelling of NS5 binding sites on the 3D structure of the WNV NS5 RdRp domain
When the putative binding sequences (identified above) were superimposed onto the crystal structure published for the WNV RdRp (PDB code 2HFZ; Malet et al., 2007) the putative binding sites for mAbs 6A10, 4B6, 5C11 and 5D4 were shown to reside on the surface of the RdRp molecule, within the fingers subdomain (Fig. 3a, b) . Further modelling of the binding site for mAbs 5D4 and 4B6, based on the requirement of residues 370-389 (corresponding to a-helix 5; see Supplementary Fig. S1 in the paper by Malet et al., 2007) and additional residues between positions 400 and 600, revealed that aa 502-506 (a-helix 10) and/or 540-560 (including a-helix 12) lie in close proximity to 370-389, and represent the most likely regions to lie in close proximity to 370-389, and represent the most likely regions to comprise the remainder of the epitope(s) ( Supplementary Fig. S3a , available in JGV Online). Competitive binding studies between the RdRpreactive mAbs further demonstrated that binding of 5D4 was enhanced (rather than inhibited) by more than twofold in the presence of 4B6, suggesting that the antibodies recognize different epitopes and that binding of 4B6 to a proximal region of the protein induces allosteric changes that increase access or affinity of 5D4 to its epitope (Fig.  4a ). We and others have reported a similar phenomenon using mAbs to the flavivirus glycoproteins E and NS1 (Heinz, 1986; Hall et al., 1990) . Enhancement of 5D4 binding (by more than twofold) in the presence of 5C11 is also consistent with the latter binding to nearby residues between positions 354 and 369 (see below).
Similar modelling of the binding site for mAb 5C11 revealed that essential residues 354-369 lie between ahelices 4 and 5 (including the C terminus of a-4) on the WNV RdRp crystal structure. The additional requirement for residues between positions 400 and 600 suggest that aa 538-550 (including the N-terminal end of a-helix 12) or 584-587 (b-sheet 2) are likely to comprise part of the epitope based on their proximity ( Supplementary Fig.  S3b ). Competitive binding between 5C11 and other NS5 mAbs also revealed that binding of 5C11 was strongly enhanced (more than fourfold) in the presence of mAb 6A10 (Fig. 4b) . This is consistent with conformational changes in the region 354-369 (and enhanced recognition of this site by 5C11) induced by binding of 6A10 to adjacent residues in the 370-389 a-helix 5. Based on the additional requirement for residues between 600 and 831 for 6A10 binding, proximity modelling from the crystal structure of WNV NS5 also predicted that amino acids between positions 640 and 657 (a-helix 15) may form part of the epitope for this antibody ( Supplementary Fig. S3c ).
The binding site for mAb 3H6 was localized to a relatively large region of the protein (residues 390-600) based on binding to the truncated recombinant proteins. While this precluded accurate modelling on the crystal structure, data from competitive binding studies revealed that 3H6 was clearly inhibited by 4B6 and 5C11 (more than threefold for both), suggesting that the binding sites for these antibodies are in close proximity (Fig. 4c) .
The binding profiles of these mAbs to four WNV strains in ELISA provide further confirmation of the putative binding sites described above. Based on the amino acid alignments deduced from the published genome sequences of these viruses, the region 350-389, which encompasses the 5C11 binding site (354) (355) (356) (357) (358) (359) (360) (361) (362) (363) (364) (365) (366) (367) (368) (369) , is identical for all four viruses, consistent with a similar binding affinity of this mAb for these WNV strains. In contrast, substitutions in WNV Sarafend and WNV B956 at residues 390 (EAD) and 392 (RAK), immediately adjacent to the predicted binding site for 6A10, 4B6, 5D4 (370-389) correspond to a lack of binding of these mAbs to these two viruses.
In summary, structural modelling of the binding sites of mAbs 5D4, 5C11, 4B6 and 6A10 to the WNV RdRp have allowed the prediction of additional contact residues that comprise conformational epitopes located in a region of the fingers subdomain of the RdRp. The competitive binding data also demonstrated that these mAbs recognize distinct epitopes that are spatially related and that the epitope recognized by mAb 3H6 is also located in this region of the RdRp domain.
Fine mapping of the 5H1 epitope using synthetic peptides
The reaction of mAb 5H1 with C-terminally truncated NS5 constructs confirmed that the epitope is contained in the (Lanciotti et al., 1999) . Synthetic peptides comprising 19 or 13 aa surrounding these residues were designed from the WNV KUN NS5 sequence or from the corresponding sequence of WNV NY99 and tested for reactivity with mAb 5H1 in ELISA (see Table 3 ). A strong reaction was observed for mAb 5H1 with the 19mer peptide designed around residue 47 in the WNV KUN NS5 amino acid sequence (KUN-NS5-47R-19), while no reaction was observed with a similar length peptide designed around residue 25 (KUN-NS5-25I-19). Furthermore, peptides representing the corresponding NY99 sequence at position 47 (NY99-NS5-47G-19), or both 47 and 49 (NY99-47R-49V-19), were recognized with dramatically reduced affinity (most diminished in the latter) by mAb 5H1, confirming a key role of these residues in the antibody binding site. Although 5H1 failed to recognize the shorter peptide (KUN-NS5-47R-13) in ELISA, further analysis of the peptide coupled to microspheres in a Luminex assay revealed significant binding of the antibody, although the level of fluorescence was roughly half that produced by the 19mer in the same assay ( Supplementary Fig. S4 , available in JGV Online). This indicates that the conformation of KUN-NS5-47R-13 is compromised after adsorbance to the solid phase in ELISA, while the extra amino acids in the longer peptide (KUN-NS5-47R-19) preserve the antigenic structure after attachment to the plastic (Hobson-Peters et al., 2008) . In summary, the peptide binding data described above indicate that a 13 aa stretch (encompassing positions 41-53 of NS5) contains the core residues of the 5H1 epitope.
Inhibition of RdRp activity by NS5-specific mAbs
The epitope mapping studies reported here have identified several mAbs that recognize and bind to amino acid sequences in the RdRp of NS5. To investigate whether the binding of these mAbs might inhibit function, in vitro RdRp assays were performed in the presence of various dilutions of hybridoma supernatants containing anti-NS5 mAbs. Non-specific inhibition produced by components of the culture medium was assessed with reference to mAb 5H1 as the control, as this antibody was shown to bind to the N-terminal MTase domain (absent in the recombinant RdRp used for this assay). While some non-specific inhibition of RdRp activity (compared with a blank control) was observed with neat culture supernatant from 5H1, no significant inhibition was observed at dilutions of 1/5 and 1/10 (Fig. 5) . By comparison, mAbs 5C11, 6A10, 4B6 and 5D4 all exhibited significant inhibition of RdRp activity at 1/5 (40-90 %) and 1/10 dilutions (30-70 %) with the most potent inhibition exhibited by 5D4 (Fig. 5) . It is worth noting that these four mAbs all recognized amino acid sequences in a 36 residue span of the fingers subdomain (354-389) of the RdRp. mAb 7G6 failed to inhibit RdRp activity, with almost identical results to all corresponding dilutions of 5H1. This is consistent with the lack of binding of 7G6 to recombinant RdRp in dot-blot assay and ELISA described earlier.
While the use of crude hybridoma culture supernatants to assess RdRp inhibition activity precluded an accurate assessment of the relative potency of mAbs in the in vitro assay, the yield of IgG purified from aliquots of these supernatants provided an estimate of the mAb concentration in each sample (see Fig. 5 legend) . These values suggest that the potent inhibition by 5D4 hybridoma supernatant, which contained the lowest concentration of IgG (approx. 50 mg ml 21 compared with 270 mg ml 21 for 5H1) was not due to the addition of an excess of mAb to the assay.
DISCUSSION
In this study, seven mAbs were produced to the NS5 protein of the Kunjin strain of WNV. Using a series of Nand C-terminally truncated recombinant NS5 proteins expressed in bacteria, the binding sites of six of these antibodies were localized to specific regions within NS5. This is the first reported mapping of antigenic sites on the flavivirus NS5 protein.
Based on reaction profiles to truncated NS5 proteins, the binding sites of five mAbs were located within the RdRp domain. Recognition of four of these antibodies required the presence of relatively short helical sequences of amino acids in the fingers subdomain (residues 354-369 for 5C11 and 370-389 for 5D4, 6A10 and 4B6). Due to the highly conformational nature of the epitopes, additional amino acid sequences between residues 400 and 600 or 600 and 831 were also required for successful recognition by these antibodies. Indeed, modelling of the epitopes using the published crystal structure of the WNV RdRp (Malet et al., 2007) indicates that these epitopes are composed of multiple protein structural elements in the RdRp domain. It is also worth noting that amino acid sequences recognized by these mAbs reside in regions of the WNV NS5 that correspond to the b-and a/b-nuclear localization signals (322-370 and 371-407, respectively) associated with nuclear localization of DENV2 NS5 (see Fig. 6 in the paper by Malet et al., 2007) . However, due to the lack of nuclear localization of NS5 in WNV-infected cells (Malet et al., 2007; Mackenzie et al., 2007; Fig. 2c) , the significance of this observation is unclear.
A single antibody (5H1) recognized NS5 in Western blot, even after the protein had been reduced and carboxymethylated. This indicated that 5H1 bound to a linear amino acid sequence (continuous epitope). This epitope was mapped to a 13 aa stretch (residues 41-53) that forms a helix-turn motif in the crystal structure of the MTase domain (Zhou et al., 2007) . This region of NS5 is of particular interest in the context of the predicted structure of the full-length NS5 protein. The model was based on the observation that substitution of residues 46, 47 and 49 in an infectious clone of DENV2 severely reduced viral replication and induced a compensatory mutation of residue 512 between the a1-a9 and a12-b3 motifs of the RdRp palm subdomain, which restored replication competence (Malet et al., 2007) . Using separate crystal structures of MTase and RdRp domains for both WNV and DENV, residues 47 and 49 in the MTase (the core residues of the epitope of 5H1) are predicted to lie in close proximity to the RdRp palm subdomain.
Of interest is the observation that site-directed mutagenesis of the C-terminally truncated recombinant protein (rNS5 1-270) to contain an RAG substitution at position 47, corresponding to the WNV NY99 sequence at this residue, was recognized with similar affinity by 5H1 as the nonmutated rNS5 1-270 protein (results not shown). This is in contrast with the almost complete abolishment of binding to native NS5 in acetone-fixed WNV NY99 -infected cells, containing a G at position 47, and to significant reduction in binding to a synthetic peptide containing the same substitution. Thus, it is tempting to assume that the Hybridoma culture supernatants were used neat or diluted as indicated. mAb 5H1, which does not recognize the recombinant RdRp domain, was included as the negative control. Approximate IgG concentrations (mg ml "1 ) for each supernatant [determined from yields of pure IgG isolated from 10 ml each supernatant using HiTrap protein G columns (GE Healthcare)] were: 5H1, 270; 5D4, 50; 7G6, 80; 5C11, 180; 3H6, 180. The lack of binding of mAb 7G6 to N-and C-terminally truncated NS5 recombinants indicates that this antibody recognizes a conformational epitope that requires the presence of at least residues 1-264 and 600-903 for complete epitope formation. Together with the observation that 7G6 exhibits significant binding to WNV-infected cells fixed in situ in the ELISA (Table 1) , the results support the predicted structural model suggesting a physical interaction between the MTase and RdRp domains in the native protein.
The data presented above suggest that both 5H1 and 7G6 may bind to regions of NS5 where interaction occurs between the MTase and RdRp domains. A possible solution to the instability of full-length recombinant NS5 during purification and crystallization may be to co-purify and crystallize with a ligand such as a reactive mAb. In this context, mAbs 5H1 and 7G6 are good candidates for this strategy.
Our findings, that mAbs recognizing defined amino acid sequences in the fingers subdomain of the WNV RdRp significantly inhibited RdRp activity in an in vitro assay, indicate that this region of the NS5 protein represents a promising target for the design of small molecules to interfere with RdRp activity in vivo. In the RdRp assay employed here, a recombinant RdRp domain was used, thus inhibition was measured in the absence of the MTase domain and other components of the replicase complex that are formed during viral infection in vivo (Westaway et al., 2002) . As a consequence, we cannot assess whether the mAbs are binding to regions of the RdRp that would be masked or sterically hindered in the full replicase complex. However, the ability of these mAbs to recognize NS5 in acetone-fixed WNV-infected cells provides evidence for their recognition of the native protein in situ. Furthermore our data are consistent with the findings of Bartholomeusz & Wright (1993) , who demonstrated inhibition of RdRp activity in infected cellular extracts in vitro using polyclonal rabbit antiserum prepared against DENV2 NS5 protein.
The data generated here provide the basis for epitope topography of the NS5 protein which supports previous predictive models of the structure of the native, full-length NS5. An accurate structural model of the native protein will greatly facilitate the design of antiviral drugs to inhibit both MTase and RdRp activity and reduce viral replication in infected cells. Our preliminary RdRp inhibition studies clearly demonstrate the value of this approach.
The identification of antigenic sites on the WNV NS5 may have additional value for the design of novel diagnostic antigens. The fact that NS5 is a reliable serological marker of WNV infection (Wong et al., 2003) suggests that further investigation of immunodominance of the epitopes identified here during human and animal infections is warranted.
